ENXTPA:ALONC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Oncodesign Société Anonyme, a biotechnology company, conducts research and development work on new therapeutic and diagnostic tools along with pharmaceutical firms, biotech companies, public research institutions, and investment groups.


Snowflake Analysis

Adequate balance sheet with proven track record.

Share Price & News

How has Oncodesign Société Anonyme's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALONC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.7%

ALONC

0.9%

FR Biotechs

5.9%

FR Market


1 Year Return

85.8%

ALONC

-14.2%

FR Biotechs

-8.3%

FR Market

Return vs Industry: ALONC exceeded the French Biotechs industry which returned -13.8% over the past year.

Return vs Market: ALONC exceeded the French Market which returned -7.9% over the past year.


Shareholder returns

ALONCIndustryMarket
7 Day1.7%0.9%5.9%
30 Day1.3%-14.0%2.6%
90 Day25.3%-3.8%-9.6%
1 Year85.8%85.8%-14.1%-14.2%-6.6%-8.3%
3 Year-6.8%-6.8%-60.9%-60.9%1.4%-6.9%
5 Year46.4%46.4%-69.5%-69.7%19.9%4.6%

Price Volatility Vs. Market

How volatile is Oncodesign Société Anonyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Oncodesign Société Anonyme undervalued compared to its fair value and its price relative to the market?

81.81x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: ALONC (€12.15) is trading above our estimate of fair value (€1.41)

Significantly Below Fair Value: ALONC is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ALONC is poor value based on its PE Ratio (81.8x) compared to the Biotechs industry average (33.5x).

PE vs Market: ALONC is poor value based on its PE Ratio (81.8x) compared to the French market (14.6x).


Price to Earnings Growth Ratio

PEG Ratio: ALONC is poor value based on its PEG Ratio (10.1x)


Price to Book Ratio

PB vs Industry: ALONC is overvalued based on its PB Ratio (10.3x) compared to the FR Biotechs industry average (3x).


Next Steps

Future Growth

How is Oncodesign Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

8.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALONC's forecast earnings growth (8.1% per year) is above the savings rate (0.6%).

Earnings vs Market: ALONC's earnings (8.1% per year) are forecast to grow slower than the French market (13% per year).

High Growth Earnings: ALONC's earnings are forecast to grow, but not significantly.

Revenue vs Market: ALONC's revenue (4.6% per year) is forecast to grow faster than the French market (3.9% per year).

High Growth Revenue: ALONC's revenue (4.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALONC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Oncodesign Société Anonyme performed over the past 5 years?

-7.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALONC has high quality earnings.

Growing Profit Margin: ALONC became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: ALONC has become profitable over the past 5 years, growing earnings by -7.9% per year.

Accelerating Growth: ALONC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ALONC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).


Return on Equity

High ROE: ALONC's Return on Equity (20.6%) is considered high.


Next Steps

Financial Health

How is Oncodesign Société Anonyme's financial position?


Financial Position Analysis

Short Term Liabilities: ALONC's short term assets (€27.3M) exceed its short term liabilities (€19.1M).

Long Term Liabilities: ALONC's short term assets (€27.3M) exceed its long term liabilities (€16.6M).


Debt to Equity History and Analysis

Debt Level: ALONC's debt to equity ratio (63.1%) is considered high.

Reducing Debt: ALONC's debt to equity ratio has increased from 1.9% to 63.1% over the past 5 years.

Debt Coverage: ALONC's debt is well covered by operating cash flow (113.6%).

Interest Coverage: ALONC's interest payments on its debt are well covered by EBIT (3.3x coverage).


Balance Sheet


Next Steps

Dividend

What is Oncodesign Société Anonyme's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALONC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALONC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALONC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALONC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALONC's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.0yrs

Average management tenure


CEO

Philippe Genne

10yrs

Tenure

€204,420

Compensation

Dr. Philippe Genne, Ph.D., Founded Oncodesign Société Anonyme, serves as its Chairman of the Board and has been its Chief Executive Officer since May 18, 2010. 


Leadership Team

NamePositionTenureCompensationOwnership
Philippe Genne
Founder10yrs€204.42kno data
Arnaud Lafforgue
Chief Financial & Administrative Officer2.08yrsno datano data
Jan Hoflack
Chief Scientific Officerno datano datano data
Catherine Genne
Deputy Managing Directorno data€24.34kno data
Olivier Duchamp
Member of Executive Board12.33yrsno datano data
Francis Bichat
Member of Executive Board12.33yrsno datano data
Xavier Morge
Chief of Business Development & Marketing2.75yrsno datano data
Thierry Billoué
Head of Human Resourcesno datano datano data
Fabrice Viviani
Head of the Experimentation Divisionno datano datano data
Alexis Denis
Head of the Discovery Divisionno datano datano data

10.0yrs

Average Tenure

58yo

Average Age

Experienced Management: ALONC's management team is seasoned and experienced (10 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Oncodesign Société Anonyme's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oncodesign Société Anonyme
  • Ticker: ALONC
  • Exchange: ENXTPA
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €82.633m
  • Shares outstanding: 6.80m
  • Website: https://www.oncodesign.com

Number of Employees


Location

  • Oncodesign Société Anonyme
  • 20 rue Jean Mazen
  • B.P. 27627
  • Dijon
  • Burgundy
  • 21076
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALONCENXTPA (Euronext Paris)YesOrdinary SharesFREURApr 2014

Biography

Oncodesign Société Anonyme, a biotechnology company, conducts research and development work on new therapeutic and diagnostic tools along with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services for proof of concept stage; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company is also involved in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. Further, the company is involved in the artificial intelligence business that support development of the drug discovery of the future and halve research and development times for drug candidates. It has a strategic partnership with Servier for the research and development of drug candidates for Parkinson’s disease; and HitGen Inc. for the identification and progression of new chemical entities. The company was founded in 1995 and is headquartered in Dijon, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/30 00:09
End of Day Share Price2020/05/29 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.